Sfoglia per Autore
Wave climate at shallow waters along the Abu Dhabi coast
2018 W. Hamza, L. Lusito, F. Ligorio, G.R. Tomasicchio, F. D'Alessandro
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
2020 E. Zattarin, R. Leporati, F. Ligorio, R. Lobefaro, A. Vingiani, G. Pruneri, C. Vernieri
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
2020 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Loberfaro, A. Belfiore, A. Vingiani, G. Pruneri, G. Bianchi, G. Capri, S. Pupa, F. de Braud, C. Vernieri
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
2020 E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F. De Braud, C. Vernieri
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
2021 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Lobefaro, A. Ottini, A. Vingiani, S.M. Pupa, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin
2021 C. Fabbroni, G. Fuca, F. Ligorio, E. Fumagalli, M. Barisella, P. Collini, C. Morosi, A. Gronchi, A.P.D. Tos, P.G. Casali, R. Sanfilippo
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
2021 F. Ligorio, G. Fuca, E. Zattarin, R. Lobefaro, L. Zambelli, R. Leporati, C. Rea, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
2021 F. Ligorio, I. Pellegrini, L. Castagnoli, A. Vingiani, R. Lobefaro, E. Zattarin, M. Santamaria, S.M. Pupa, G. Pruneri, F. de Braud, C. Vernieri
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report
2021 E. Zattarin, F. Ligorio, F. Nichetti, G. Bianchi, G. Capri, F. de Braud
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
2022 F. Ligorio, S. Di Cosimo, P. Verderio, C.M. Ciniselli, S. Pizzamiglio, L. Castagnoli, M. Dugo, B. Galbardi, R. Salgado, S. Loi, S. Michiels, T. Triulzi, E. Tagliabue, S. El-Abed, M. Izquierdo, E. de Azambuja, P. Nuciforo, J. Huober, L. Moscetti, W. Janni, M.A. Coccia-Portugal, P.A. Corsetto, A. Belfiore, D. Lorenzini, M.G. Daidone, A. Vingiani, L. Gianni, S.M. Pupa, G. Bianchini, G. Pruneri, C. Vernieri
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
2022 F. Ligorio, G. Fucà, L. Provenzano, R. Lobefaro, L. Zanenga, A. Vingiani, A. Belfiore, A. Lorenzoni, A. Alessi, G. Pruneri, F. de Braud, C. Vernieri
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison
2023 R. Lobefaro, L. Mariani, G. Peverelli, F. Ligorio, G. Fuca, A. Rametta, E. Zattarin, R. Leporati, D. Presti, B. Cantarelli, C. Depretto, A. Vingiani, S. Manoukian, G. Scaperrotta, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile